There are two main types of lung cancer: small cell and non-small cell. According to the American Cancer Society, non-small cell lung cancer is often categorized in one of two stages: limited or ...

Racura Oncology has dosed the first patient in the HARNESS-1 Phase 1a/b trial of RC220 in combination with osimertinib for ...

Most people with small cell lung cancer will have a recurrence. While several factors affect life expectancy, the outlook is typically less favorable. Treatment for recurrent small cell lung cancer is ...

The study aimed to explore the distribution of circulating tumor cells (CTCs), circulating tumor endothelial cells (CTECs), and their subtypes in non-cancer and bladder cancer individuals, focusing on ...

Early-stage non-small cell lung cancer (NSCLC) has a better prognosis than advanced stages. Staging the disease helps inform treatment by factoring in tumor size, lymph node involvement, and spread.

Small cell lung cancer (SCLC) is rarer than non-small cell lung cancer (NSCLC) but tends to be more difficult to treat. SCLC can be more resistant and aggressive than other cancers, which can increase ...

New T-cell engagers and ADCs show survival gains in pretreated small cell lung cancer, signaling long-awaited progress and more treatment options for patients. New therapies like T-cell engagers and ...

Small cell lung cancer (SCLC), an aggressive neuroendocrine malignancy, exhibits high intertumoral heterogeneity and limited treatment options. Immune checkpoint inhibitors (ICIs) provide only modest ...

Part C domestic enrollment is underway at three clinical sites in the U.S. CHICAGO, June 25, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical ...

Small cell lung cancer (SCLC) staging helps doctors determine how advanced the cancer is and choose the best treatment approach. Doctors typically classify SCLC into two stages: limited, where cancer ...